In March 2024, Lantern dosed two subjects in a Phase Ia/Ib trial of LP-284 for relapsed or refractory non-Hodgkin’s lymphoma ...

Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics ...

The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

Alterity Therapeutics reports positive topline results from open-label phase II clinical trial of lead drug ATH434 in ...

Aclaris Therapeutics announces positive top-line results from phase 2a clinical trial of ATI-2138: Wayne, Pennsylvania Friday, August 1, 2025, 14:00 Hrs [IST] Aclaris Therapeutics ...

ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ...

CLL-314 trial compared the efficacy and safety of pirtobrutinib with ibrutinib in adults with CLL/SLL who were treatment-naïve or who were previously treated and were BTK inhibitor-naïve.

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Background: The signal regulatory protein alpha (SIRPα)/CD47 axis is a critical regulator of myeloid cell activation and serves as a myeloid-specific immune checkpoint, making it a potential ...

An open-label, phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma. Authors: ...

“We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial,” said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics.